ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Coronary disease

April 11, 2020
The authors present a meta-analysis of randomized controlled trials regarding the outcome of ticagrelor-based antiplatelet therapies in patients after coronary artery bypass graft (CABG) surgery. They found a reduced rate of major adverse cardiac events and a reduced mortality in these patients receiving aspirin and/or clopidogrel.
April 1, 2020
Short but promising follow-up: the intervention appears again to trade off short-term peripheral vascular complications for hitherto semi-qualified MAJOR bleed in patients undergoing revascularization for peripheral vascular disease, for an assumed considerable financial cost.
March 10, 2020
In this educational video, the authors explain how to detect an intramyocardial left anterior descending coronary artery on angiography.
March 1, 2020
A very easy-to-read editorial that digests a manuscript on the IMPROVE study.
February 20, 2020
This study of Medicare beneficiaries evaluated how often CABG was performed related to narrow intervals around a patient's birthday.
January 21, 2020
The authors demonstrate the technique of endoscopic radial artery harvesting.
January 1, 2020
In the ongoing debate about the results of the EXCEL trial in which Professor Taggart withdrew his authorship and EACTS withdrew their support for the recommendations regarding PCI versus CABG, we previously posted the response from the EXCEL remaining coauthors : 
December 19, 2019
Following the withdrawal of the support of EACTS for the left main stem chapter of the EACTS/ESC Chapter of the revascularisation guidelines following the BBC Newsnight documentary of this, and the withdrawal of Professor David Taggart as an author of the EXCEL trial published in the NEJM, the EXCEL trial authors have published a very robust defence
December 17, 2019
Drs Patrick Myers, David Taggart, and Michael Mack discuss the ORBITA trial, focusing on the importance of the sham-control design of the trial, ORBITA's context within previous and upcoming trials, and what the results mean for cardiac surgeons.

Pages